Targeted therapies for metastatic melanoma.
The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.
NYU School of Medicine, New York, NY 10016, USA.
Sunandana
S
Chandra
Anna C
AC
Pavlick
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007211:Indoles / Q000627:therapeutic use; D000074324:Ipilimumab; D020935:MAP Kinase Signaling System / Q000235:genetics / Q000276:immunology; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D058990:Molecular Targeted Therapy / Q000379:methods*; D018426:SEER Program; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D013449:Sulfonamides / Q000627:therapeutic use; D000077484:Vemurafenib; D048490:raf Kinases / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D007211:Indoles; D000074324:Ipilimumab; D013449:Sulfonamides; D000077484:Vemurafenib; D048490:raf Kinases